J&J's new prostate cancer pill shrinks tumors in early trial

Johnson & Johnson (JNJ) said its once-daily pill JNJ-6143 shrank or cleared tumors in 69% of advanced prostate cancer patients with measurable disease, in an early trial shown October 24. The drug came from J&J's roughly $3 billion Halda buy. Lloyd Doggett holds the stock.

Sources

J&J's Oral Prostate Cancer Pill JNJ-6143, Bought With Halda, Shrinks Tumors in 69% of Measurable Patients in Early Trial at ESMO
The whole story · updated
R
Reuters
·
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in